| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
|
Lancet Oncol
|
2013
|
2.72
|
|
2
|
Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1.
|
Cancer Discov
|
2012
|
2.53
|
|
3
|
Stringent control of gene expression in vivo by using novel doxycycline-dependent trans-activators.
|
Hum Gene Ther
|
2002
|
1.50
|
|
4
|
Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors.
|
J Med Chem
|
2009
|
1.35
|
|
5
|
Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.
|
Mol Cancer Ther
|
2013
|
1.35
|
|
6
|
Construction of an rtTA2(s)-m2/tts(kid)-based transcription regulatory switch that displays no basal activity, good inducibility, and high responsiveness to doxycycline in mice and non-human primates.
|
Mol Ther
|
2003
|
1.11
|
|
7
|
Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition.
|
Cancer Cell Int
|
2012
|
1.06
|
|
8
|
Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain Inhibitor.
|
J Med Chem
|
2015
|
0.96
|
|
9
|
Helper-dependent adenovirus for the gene therapy of proliferative retinopathies: stable gene transfer, regulated gene expression and therapeutic efficacy.
|
J Gene Med
|
2007
|
0.90
|
|
10
|
Inhibition of retinal and choroidal neovascularization by a novel KDR kinase inhibitor.
|
Mol Vis
|
2005
|
0.90
|
|
11
|
Electro-gene-transfer: a new approach for muscle gene delivery.
|
Somat Cell Mol Genet
|
2002
|
0.89
|
|
12
|
Identification of substituted pyrazolo[1,5-a]quinazolin-5(4H)-one as potent poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors.
|
Bioorg Med Chem Lett
|
2009
|
0.88
|
|
13
|
MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation.
|
Invest New Drugs
|
2011
|
0.87
|
|
14
|
A functionally orthogonal estrogen receptor-based transcription switch specifically induced by a nonsteroid synthetic ligand.
|
Chem Biol
|
2005
|
0.86
|
|
15
|
A structure-guided approach to an orthogonal estrogen-receptor-based gene switch activated by ligands suitable for in vivo studies.
|
J Med Chem
|
2006
|
0.85
|
|
16
|
Long-term and tight control of gene expression in mouse skeletal muscle by a new hybrid human transcription factor.
|
Mol Ther
|
2002
|
0.78
|
|
17
|
A multiplexed siRNA screening strategy to identify genes in the PARP pathway.
|
J Biomol Screen
|
2012
|
0.77
|
|
18
|
A zinc finger nuclease assay to rapidly quantitate homologous recombination proficiency in human cell lines.
|
Anal Biochem
|
2012
|
0.76
|
|
19
|
Discovery and SAR of novel, potent and selective hexahydrobenzonaphthyridinone inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1).
|
Bioorg Med Chem Lett
|
2009
|
0.76
|
|
20
|
Synthesis and biological evaluation of substituted 2-phenyl-2H-indazole-7-carboxamides as potent poly(ADP-ribose) polymerase (PARP) inhibitors.
|
Bioorg Med Chem Lett
|
2009
|
0.76
|
|
21
|
Synthetic lethality of PARP inhibition in BRCA-network disrupted tumor cells is associated with interferon pathway activation and enhanced by interferon-γ.
|
Apoptosis
|
2012
|
0.75
|
|
22
|
Development of substituted 6-[4-fluoro-3-(piperazin-1-ylcarbonyl)benzyl]-4,5-dimethylpyridazin-3(2H)-ones as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors active in BRCA deficient cells.
|
Bioorg Med Chem Lett
|
2009
|
0.75
|
|
23
|
Identification of aminoethyl pyrrolo dihydroisoquinolinones as novel poly(ADP-ribose) polymerase-1 inhibitors.
|
Bioorg Med Chem Lett
|
2009
|
0.75
|
|
24
|
Identification and SAR of novel pyrrolo[1,2-a]pyrazin-1(2H)-one derivatives as inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1).
|
Bioorg Med Chem Lett
|
2009
|
0.75
|